M1469 Patient has a history of hepatitis b illness or received a hepatitis b surface antigen, hepatitis b surface antibody, or total antibody to hepatitis b core antigen test with a positive result any time before or during the measurement period
Billable / valid for submission HCPCS Release 2026Q3
Short description: Hx of hep b, or pos bld test
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Patient has a history of hepatitis b illness or received a hepatitis b surface antigen, hepatitis b surface antibody, or total antibody to hepatitis b core antigen test with a positive result any time before or during the measurement period | yes |
Related codes in M14
- M1400 Patients who died during the follow-up period
- M1401 Stages i-iii breast cancer
- M1402 Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1403 Patients with baseline and follow-up promis surveys documented in the medical record
- M1404 Patients on a therapeutic clinical trial
- M1405 Patients with recurrence/disease progression
- M1406 Patients who leave the practice during the follow-up period
- M1407 Patients who died during the follow-up period
- M1408 Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
- M1409 Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1410 Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411 Currently on first-line immune checkpoint inhibitors without chemotherapy
- M1412 Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
- M1413 Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
- M1414 Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is in an urgent or emergent situation where delay of treatment would jeopardize the patient's health status; other medical reasons/contraindication)
- M1415 Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
- M1416 Patient received hospice services any time during the performance period
- M1417 Patients who are up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination
- M1418 Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination because of a medical contraindication documented by clinician
- M1419 Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination